The predictive role of TMB assessed by next generation sequencing (NGS) was explored in a retrospective study that used targeted sequencing data to assess the impact of TMB on ICIs efficacy (anti PD-1 and/or anti-CTLA4) in a cohort of patients with relapsed/refractory SCLC. The gene discussed is PDCD1; the disease is small cell lung carcinoma.